Skip to main content
. 2020 Jul 12;12(7):1875. doi: 10.3390/cancers12071875

Figure 2.

Figure 2

Schematic overview of adoptive cell therapies. T cells or NK cells can be isolated from the patient, or from healthy donors, and expanded ex vivo. During this process, they can be genetically engineered to express a CAR or TCR variant. Upon infusion, these killer cells can reinforce the existing immune response or effect a new one.